Van Kooten v. Secretary of Health and Human Services ( 2016 )


Menu:
  •                   In the United States Court of Federal Claims
    OFFICE OF SPECIAL MASTERS
    No. 14-923V
    *************************
    *
    MARY VAN KOOTEN,           *
    *                                      Filed: June 20, 2016
    Petitioner, *
    *                                      Decision by Stipulation; Damages;
    v.               *                                      Tetanus-diphtheria-acellular-pertussis
    *                                      (“Tdap”) Vaccine; Transverse Myelitis
    SECRETARY OF HEALTH        *                                      (“TM”).
    AND HUMAN SERVICES,        *
    *
    Respondent. *
    *
    *************************
    Alison H. Haskins, Maglio Christopher and Toale, PA, Sarasota, FL, for Petitioner.
    Camille M. Collett, U.S. Dep’t of Justice, Washington, DC, for Respondent.
    DECISION AWARDING DAMAGES1
    On September 29, 2014, Mary Van Kooten filed a petition seeking compensation under the
    National Vaccine Injury Compensation Program (“Vaccine Program”).2 Petitioner alleges that she
    suffered from transverse myelitis (“TM”) as a result of her May 17, 2013, receipt of the tetanus-
    diphtheria-acellular-pertussis (“Tdap”) vaccine. Moreover, Petitioner alleges that she experienced
    residual effects of this injury for more than six months.
    Respondent denies that the Tdap vaccine caused Petitioner’s alleged TM or any other injury
    or condition. Nonetheless both parties, while maintaining their above-stated positions, agreed in a
    stipulation (filed on June 16, 2016) that the issues before them could be settled, and that a decision
    should be entered awarding Petitioner compensation.
    1
    Because this decision contains a reasoned explanation for my actions in this case, I will post it on the United States
    Court of Federal Claims website, in accordance with the E-Government Act of 2002, 
    44 U.S.C. § 3501
     (2012). As
    provided by 42 U.S.C. § 300aa-12(d)(4)(B), however, the parties may object to the decision’s inclusion of certain kinds
    of confidential information. Specifically, under Vaccine Rule 18(b), each party has fourteen days within which to request
    redaction “of any information furnished by that party: (1) that is a trade secret or commercial or financial in substance
    and is privileged or confidential; or (2) that includes medical files or similar files, the disclosure of which would constitute
    a clearly unwarranted invasion of privacy.” Vaccine Rule 18(b). Otherwise, the whole decision will be available to the
    public. Id.
    2
    The Vaccine Program comprises Part 2 of the National Childhood Vaccine Injury Act of 1986, Pub. L. No. 99-660, 
    100 Stat. 3758
    , codified as amended at 42 U.S.C. §§ 300aa-10 through 34 (2012) (“Vaccine Act” or “the Act”). Individual
    section references hereafter will be to § 300aa of the Act (but will omit that statutory prefix).
    I have reviewed the file, and based upon that review, I conclude that the parties’ stipulation
    (as attached hereto) is reasonable. I therefore adopt it as my decision in awarding damages on the
    terms set forth therein.
    The stipulation awards:
       A lump sum of $220,000.00 in the form of a check payable to Petitioner.
    Stipulation ¶ 8. This amounts represents compensation for all damages that would be available under
    Section 15(a) of the Act.
    I approve a Vaccine Program award in the requested amount set forth above to be made to
    Petitioner. In the absence of a motion for review filed pursuant to RCFC Appendix B, the clerk of the
    court is directed to enter judgment herewith.3
    IT IS SO ORDERED.
    /s/ Brian H. Corcoran
    Brian H. Corcoran
    Special Master
    3
    Pursuant to Vaccine Rule 11(a), the parties may expedite entry of judgment by each filing (either jointly or separately)
    a notice renouncing their right to seek review.
    2
    

Document Info

Docket Number: 14-923

Filed Date: 8/8/2016

Precedential Status: Non-Precedential

Modified Date: 4/17/2021